Literature DB >> 6133298

Tardive dyskinesia: a 3-year follow-up study.

T R Barnes, T Kidger, S M Gore.   

Abstract

A prospective study of tardive dyskinesia was carried out to gain information regarding the natural history of the condition and to identify risk factors. Out of an original cohort of 182 psychiatric patients receiving maintenance antipsychotic drugs 99 were available for reassessment after 3 years. In this follow-up group the point prevalence of oro-facial dyskinesia increased from 39% to 47% over the 3-year period. Twenty-two patients developed the disorder, while remission occurred in 14 others. Risk factors predicting the presence of oro-facial dyskinesia at follow-up included being over 50 years of age and the presence of akathisia. There was no convincing association between the duration of antipsychotic drug treatment and the presence or severity of oro-facial dyskinesia. Patients receiving over 1000 mg chlorpromazine equivalents of antipsychotic drug per day were unlikely to have the condition. The amount of purposeless trunk and limb movement present proved to be a relatively stable phenomenon, showing only a slight increase with age and no change over the follow-up period. The implications of these findings are discussed, with particular consideration being given to the effects of loss of patients to follow-up.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6133298     DOI: 10.1017/s003329170005008x

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  12 in total

1.  A prospective study of tardive dyskinesia in Japan.

Authors:  T Inada; K Ohnishi; M Kamisada; G Matsuda; O Tajima; Y Yanagisawa; K Hashiguchi; S Shima; Y Oh-e; Y Masuda
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

Review 2.  Tardive dyskinesia.

Authors:  T R Barnes
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-16

3.  Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.

Authors:  Stanley N Caroff; Vicki G Davis; Del D Miller; Sonia M Davis; Robert A Rosenheck; Joseph P McEvoy; E Cabrina Campbell; Bruce L Saltz; Silvana Riggio; Miranda H Chakos; Marvin S Swartz; Richard S E Keefe; T Scott Stroup; Jeffrey A Lieberman
Journal:  J Clin Psychiatry       Date:  2010-08-10       Impact factor: 4.384

Review 4.  Adverse effects of antipsychotic drugs.

Authors:  A K Malhotra; R E Litman; D Pickar
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

Review 5.  Drug treatment of resistant schizophrenia. Limitations and recommendations.

Authors:  A E Farmer; A Blewett
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

6.  Persistent akathisia associated with early tardive dyskinesia.

Authors:  T R Barnes; W M Braude
Journal:  Postgrad Med J       Date:  1984-05       Impact factor: 2.401

7.  Variation in oro-facial tardive dyskinesia during depot antipsychotic drug treatment.

Authors:  T R Barnes; D H Wiles
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

8.  Effects of tiapride in tardive dyskinesia.

Authors:  P Pollak; J M Gaio; M Hommel; J Pellat; J Perret
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

9.  Remoxipride, a selective dopamine D2 receptor antagonist, in tardive dyskinesia.

Authors:  U Andersson; J E Häggström; M I Nilsson; E Widerlöv
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 10.  Tardive dyskinesia.

Authors:  D E Casey
Journal:  West J Med       Date:  1990-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.